https://novaprd-lb.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:36361 Wed 24 May 2023 12:19:20 AEST ]]> Proteins Annexin A2 and PSA in prostate cancer biopsies do not predict biochemical failure https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:33534 Wed 23 Feb 2022 16:05:22 AEDT ]]> A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:7607 Wed 11 Apr 2018 15:15:09 AEST ]]> Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:21794 9 months or TTBF > 3 years. Conclusion: TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy. External validation, particularly in long-term AST and radiotherapy datasets, is necessary.]]> Wed 11 Apr 2018 15:10:15 AEST ]]> Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:18510 Wed 11 Apr 2018 14:04:35 AEST ]]> Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:30211 Wed 09 Feb 2022 15:53:54 AEDT ]]> Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:42275 Tue 07 Nov 2023 11:20:11 AEDT ]]> Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:7893 Sat 24 Mar 2018 10:44:59 AEDT ]]> PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer? https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:7230 Sat 24 Mar 2018 08:40:27 AEDT ]]> Survival benefit confirmed for prostate cancers diagnosed by PSA testing (letter) https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:8356 Sat 24 Mar 2018 08:39:51 AEDT ]]> Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking? https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:7789 Sat 24 Mar 2018 08:39:20 AEDT ]]> Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:7041 Sat 24 Mar 2018 08:37:55 AEDT ]]> A methodology for the analysis of PSA response signatures https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:12305 Sat 24 Mar 2018 08:11:35 AEDT ]]> Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:21389 Sat 24 Mar 2018 08:05:04 AEDT ]]> Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:21390 p< 0.001) in urinary dysfunction were measured using the EORTC PR25 instrument at 18 and 36 months. Conclusion: Adjuvant androgen suppression, bisphosphonates and increasing EBRT dose did not increase rectal or urinary dysfunction in this trial. However dose escalation using HDRB increased urinary dysfunction.]]> Sat 24 Mar 2018 08:05:03 AEDT ]]> A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:18126 Sat 24 Mar 2018 08:04:29 AEDT ]]> Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:18127 Sat 24 Mar 2018 08:04:29 AEDT ]]> A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:17463 5 yr postdiagnosis on physical functioning.Design, setting, and participants. Between 2010 and 2011, 100 long-term PCa survivors from Trans-Tasman Radiation Oncology Group 03.04 Randomised Androgen Deprivation and Radiotherapy previously treated with androgen-deprivation therapy and radiation therapy were randomly assigned to 6 mo of supervised exercise followed by 6 mo of a home-based maintenance programme (n = 50) or printed educational material about physical activity (n = 50) for 12 mo across 13 university-affiliated exercise clinics in Australia and New Zealand. Intervention: Supervised resistance and aerobic exercise or printed educational material about physical activity. Outcome measurements and statistical analysis: The primary end point was a 400-m walk as a measure of cardiovascular fitness. Secondary end points were physical function, patient-reported outcomes, muscle strength, body composition, and biomarkers. Analysis of covariance was used to compare outcomes for groups at 6 and 12 mo adjusted for baseline values. Results and limitations: Participants undergoing supervised exercise showed improvement in cardiorespiratory fitness performance at 6 mo (−19 s [p = 0.029]) and 12 mo (−13 s [p = 0.028]) and better lower-body physical function across the 12-mo period (p < 0.01). Supervised exercise also improved self-reported physical functioning at 6 (p = .006) and 12 mo (p = 0.002), appendicular skeletal muscle at 6 mo (p = 0.019), and objective measures of muscle strength at 6 and 12 mo (p < 0.050). Limitations included the restricted number of participants undertaking body composition assessment, no blinding to group assignment for physical functioning measures, and inclusion of well-functioning individuals. Conclusions: Supervised exercise training in long-term PCa survivors is more effective than physical activity educational material for increasing cardiorespiratory fitness, physical function, muscle strength, and self-reported physical functioning at 6 mo. Importantly, these benefits were maintained in the long term with a home-based programme with follow-up at 12 mo. Clinical trial registry: The effect of an exercise intervention on cardiovascular and metabolic risk factors in prostate cancer patients from the RADAR study, ACTRN: ACTRN12609000729224.]]> Sat 24 Mar 2018 08:04:06 AEDT ]]> Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:5594 Sat 24 Mar 2018 07:49:21 AEDT ]]> The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:28140 Sat 24 Mar 2018 07:36:38 AEDT ]]> Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:23364 0.5 ng/mL) alone and when assessed in conjunction with the randomised treatment group increased risk of PCSM in the US trial (PSA nadir p=0.0016; PSA end p=0.017) and Australasian trial (PSA nadir p<0.0001; PSA end p=0.0012). In both trials, the randomised treatment group was no longer associated with PCSM (p>=0.20) when the candidate surrogates were included in the model. Therefore, both PSA metrics satisfied Prentice criteria for surrogacy. INTERPRETATION: After radiotherapy and 6 months of androgen suppression, men with PSA end values exceeding 0.5 ng/mL should be considered for long-term androgen suppression and those with localised or locally advanced prostate cancer with PSA nadir values exceeding 0.5 ng/mL should be considered for inclusion in randomised trials investigating the use of drugs that have extended survival in castration-resistant metastatic prostate cancer.]]> Sat 24 Mar 2018 07:16:30 AEDT ]]> Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:22823 Sat 24 Mar 2018 07:16:10 AEDT ]]>